Pulmonx
PublicPulmonx is now publicly traded
The data on this page reflects Pulmonx's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Oct 5, 2020
Last Round
Debt
Feb 1, 2023
Total Funding Raised
$555.2M
Company Overview
Pulmonx (NAS: LUNG) is a medical technology company that offers minimally invasive treatments for severe emphysema, including the Zephyr Endobronchial Valve and associated assessment systems.
Sector
Healthcare
AI Layer
Application
Keywords
Pulmonx Comparables
Compare Pulmonx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Apreo Health | 76% | |
| Free Flow Medical, Inc. | 74% | |
| Nuvaira | 72% |
Pulmonx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Feb 1, 2023 | ||||
| IPO | Oct 5, 2020 | ||||
| Convertible Debt | May 5, 2020 | ||||
| Series G | May 9, 2019 | ||||
| Series F Extension | Jan 1, 2017 | ||||
Series F | May 1, 2016 |
Key People
Founding team and executive leadership
Pulmonx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Canaccord Genuity | IPO |
| Ally Bridge Group | Convertible Debt, Series G |
| MedVenture Associates | Series A, Series D, Series C, Series B, Series E |
| BofA Securities | IPO |
| CIBC Innovation Banking | Debt, Convertible Debt |
| HealthCap | Series D, Series E, Series C |
| Morgan Stanley | IPO |
Pulmonx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access